BDBM108117 US8598206, Table 6, 2
SMILES NC(=N)c1ccc(CNC(=O)[C@H](CCC2CCNCC2)NC(=O)[C@@H](CCCc2ccncc2)NS(=O)(=O)Cc2ccccc2)cc1
InChI Key InChIKey=VNKFZBCCJJVXJG-IOWSJCHKSA-N
Data 11 KI
Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB
Found 11 hits for monomerid = 108117
Affinity DataKi: 0.400nMAssay Description:The inhibitory effect for the individual enzymes was determined in analogy to a previously disclosed method (Stürzebecher et al., J. Med. Chem.,...More data for this Ligand-Target Pair
Affinity DataKi: 2.70nMAssay Description:The inhibitory effect for the individual enzymes was determined in analogy to a previously disclosed method (Stürzebecher et al., J. Med. Chem.,...More data for this Ligand-Target Pair
Affinity DataKi: 500nMAssay Description:Inhibition of human FXIa was determined by the method described in [0092]-[0098] using activated human Factor XI from Enzyme Research Laboratories at...More data for this Ligand-Target Pair
Affinity DataKi: 600nMAssay Description:Inhibition of human aPC was determined by the method described in [0092]-[0098] using human activated protein C from Enzyme Research Laboratories at ...More data for this Ligand-Target Pair
Affinity DataKi: 850nMAssay Description:Inhibition of human FXa was determined by the method described in [0092]-[0098] using activated human Factor X from Enzyme Research Laboratories at 5...More data for this Ligand-Target Pair
TargetTranscription initiation factor IIA subunit 1(Homo sapiens (Human))
The Medicines Company (Leipzig)
US Patent
The Medicines Company (Leipzig)
US Patent
Affinity DataKi: 1.20E+3nMAssay Description:Inhibition of human FIIa was determined by the method described in [0092]-[0098] using human alpha-thrombin from Enzyme Research Laboratories at 0.1 ...More data for this Ligand-Target Pair
Affinity DataKi: 1.50E+3nMAssay Description:Inhibition of human alpha-FXIIa was determined by the method described in [0092]-[0098] using activated human alpha-Factor XII (activated Hageman Fac...More data for this Ligand-Target Pair
TargetTissue-type plasminogen activator(Homo sapiens (Human))
The Medicines Company (Leipzig)
US Patent
The Medicines Company (Leipzig)
US Patent
Affinity DataKi: 2.30E+3nMAssay Description:Inhibition of human t-PA was determined by the method described in [0092]-[0098] using recombinant human tissue-type plasminogen activator (Actilyse&...More data for this Ligand-Target Pair
Affinity DataKi: 4.95E+3nMAssay Description: Inhibition of human C1s was determined by the method described in [0092]-[0098] using native human activated C1s complement component from Calbioche...More data for this Ligand-Target Pair
Affinity DataKi: >5.00E+4nMAssay Description:Inhibition of human C1r was determined by the method described in [0092]-[0098] using native human activated C1r complement component from Calbiochem...More data for this Ligand-Target Pair
Affinity DataKi: >8.00E+4nMAssay Description:Inhibition of human t-PA was determined by the method described in [0092]-[0098] using recombinant human tissue-type plasminogen activator (Actilyse&...More data for this Ligand-Target Pair